

## MZ1, BRD4 degrader

Catalog	Unit
TBI5090-1MG	1 mg
TBI5090-5MG	5 mg

### Product Details

**Formal Name:** (2S,4R)-1-((S)-2-(tert-Butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

**Molecular Formula:** C<sub>49</sub>H<sub>60</sub>ClN<sub>9</sub>O<sub>8</sub>S<sub>2</sub>

**Formula Weight:** 1002.6

**CAS Number:** 1797406-69-9


**Purity:** >98%

**Formulation:** Powder

**Solubility:** Soluble in DMSO (up to at least 100 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years



### Applications

BRD4 degrader

### Functions

MZ1 consists of JQ1 tethered to a ligand for the E3 ubiquitin ligase VHL and is a selective degrader of the BET bromodomain protein BRD4. It rapidly and potently induces reversible, long-lasting and unexpectedly selective degradation of BRD4 over BRD2 and BRD3. It exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B. An important tool for studying the effects of BRD4 degradation in cancer therapy.

### Application Procedures

First dissolved in Soluble in DMSO (up to at least 100 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 2 months.

**For research use only.**